{"schema_version":"1","generated_at":"2026-10-28T13:01:59.023Z","data_as_of":null,"url":"https://www.findmykol.com/kol/scott-pruitt","json_url":"https://www.findmykol.com/kol/scott-pruitt/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"scott-pruitt","name":"Scott Pruitt","credential":"MD, PhD","specialty":"Surgical Oncology","specialty_raw":"Surgical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Merck & Co.","institution_url":"https://www.findmykol.com/institution/merck-co","city":"Durham","state":"NC","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1790726941","openalex":"A5112320058"},"summary":"Scott Pruitt is an Oncology physician affiliated with Merck & Co.. OpenAlex indexes 118 publications with 8,840 citations (h-index 38); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":118,"cited_by_count":8840,"h_index":38,"latest_activity_year":2022,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT01216436","title":"Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma","phase":"PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"Duke University","source_url":"https://clinicaltrials.gov/study/NCT01216436","trial_url":"https://www.findmykol.com/trial/NCT01216436"},{"nct":"NCT00672542","title":"Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"Scott Pruitt","source_url":"https://clinicaltrials.gov/study/NCT00672542","trial_url":"https://www.findmykol.com/trial/NCT00672542"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Takeda Pharmaceuticals U.S.A., Inc.","program_year":2022,"amount_usd":27.31,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1790726941"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1790726941","source":"payments"},"funding":{"award_count":1,"fiscal_years":{"first":1992,"last":1999},"rows_total":5,"shown":3,"withheld":2,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"K11AI001092","title":"IMMUNE RESPONSE TO BREAST DUCTAL CARCINOMA IN SITU","fiscal_year":1999,"organization":"DUKE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/K11AI001092"},{"project":"K11AI001092","title":"IMMUNE RESPONSE TO BREAST DUCTAL CARCINOMA IN SITU","fiscal_year":1998,"organization":"DUKE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/K11AI001092"},{"project":"K11AI001092","title":"IMMUNE RESPONSE TO BREAST DUCTAL CARCINOMA IN SITU","fiscal_year":1997,"organization":"DUKE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/K11AI001092"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors","year":2020,"journal":"JAMA Network Open","source_url":"https://doi.org/10.1001/jamanetworkopen.2020.25109","status":"verified"},{"title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","year":2019,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.19.02105","status":"verified"},{"title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","year":2019,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.18.01265","status":"verified"},{"title":"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.","year":2019,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.2523","status":"verified"},{"title":"Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.","year":2019,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2019.37.4_suppl.190","status":"verified"}],"source":"works"},"contact":{"address_1":"508 FULTON ST","address_2":"DURHAM VA MEDICAL CENTER","city":"Durham","state":"NC","zip":"277053875","phone":"919-684-3942","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1790726941","source":"identity"},"similar":[{"name":"Ednan Bajwa","slug":"ednan-bajwa","institution":"Merck & Co.","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/ednan-bajwa","json_url":"https://www.findmykol.com/kol/ednan-bajwa/profile.json"},{"name":"Annaswamy Raji","slug":"annaswamy-raji","institution":"Merck & Co.","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/annaswamy-raji","json_url":"https://www.findmykol.com/kol/annaswamy-raji/profile.json"},{"name":"Ritu Valiyil","slug":"ritu-valiyil","institution":"Merck & Co.","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/ritu-valiyil","json_url":"https://www.findmykol.com/kol/ritu-valiyil/profile.json"},{"name":"William F. Keane","slug":"william-keane","institution":"Merck & Co.","url":"https://www.findmykol.com/kol/william-keane","json_url":"https://www.findmykol.com/kol/william-keane/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"funding":2,"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2007-07-08","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}